[The use of myelopid in the combined treatment of infectious-inflammatory complications in the postoperative period in neuro-oncology patients].
Clinical observations over 48 neurosurgical patients with infectious inflammatory complications and study of their immune status showed that a course of immunocorrective therapy with myelopid produces a favourable clinical effect and normalizes the patient's immune status. Myelopid causes the best normalizing effect in patients with nontumorous pathology of the central nervous system and in extracerebral neoplasms.